Elevance Health, Inc.
ELV
$418.24
-$3.81-0.90%
| Weiss Ratings | ELV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Fair | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | C | |||
| Rating Factors | ELV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Fair | |||
| Growth Index | Weak | |||
| Efficiency Index | Excellent | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ELV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.19 | |||
| Price History | ELV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 6.13% | |||
| 30-Day Total Return | 3.54% | |||
| 60-Day Total Return | 8.86% | |||
| 90-Day Total Return | 2.22% | |||
| Year to Date Total Return | 14.73% | |||
| 1-Year Total Return | -16.48% | |||
| 2-Year Total Return | -6.81% | |||
| 3-Year Total Return | -5.67% | |||
| 5-Year Total Return | 73.59% | |||
| 52-Week High % Change | -25.60% | |||
| 52-Week Low % Change | 16.52% | |||
| Price | ELV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $567.26 | |||
| 52-Week Low Price | $362.21 | |||
| 52-Week Low Price (Date) | Dec 19, 2024 | |||
| 52-Week High Price (Date) | Sep 03, 2024 | |||
| Valuation | ELV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 95.95B | |||
| Enterprise Value | 122.12B | |||
| Price/Earnings (TTM) | 16.48 | |||
| Earnings Per Share (TTM) | 25.61 | |||
| Earnings Per Share Growth | 1.74% | |||
| Price/Earnings To Growth | 9.47 | |||
| Price/Sales (TTM) | 0.55 | |||
| Price/Book (Q) | 2.32 | |||
| Enterprise Value/Revenue (TTM) | 0.69 | |||
| Price | $417.97 | |||
| Enterprise Value/EBITDA (TTM) | 11.53 | |||
| Enterprise Value/EBIT | 13.28 | |||
| Market Cap Category | Large Cap | |||
| Dividends and Shares | ELV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 231.10M | |||
| Dividend Yield | 1.56% | |||
| Div. Per Share (Most Recent) | $1.71 | |||
| Dividend Per Share (TTM) | $6.60 | |||
| Payout Ratio (TTM) | 25.22% | |||
| Dividend Per Share (Most Recent) | $1.71 | |||
| Company Info | ELV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 833 401 1577 | |||
| Address | 220 Virginia Avenue Indianapolis, IN 46204 | |||
| Website | www.elevancehealth.com | |||
| Country | United States | |||
| Year Founded | 2001 | |||
| Profitability | ELV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 5.20% | |||
| Profit Margin | 3.38% | |||
| Management Effectiveness | ELV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 5.09% | |||
| Return on Equity | 14.77% | |||
| Income Statement | ELV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 146.22B | |||
| Total Revenue (TTM) | 176.81B | |||
| Revenue Per Share | $765.08 | |||
| Gross Profit (TTM) | 49.24B | |||
| EBITDA (TTM) | 10.59B | |||
| EBIT (TTM) | 9.20B | |||
| Net Income (TTM) | 5.98B | |||
| Net Income Avl. to Common (TTM) | 5.98B | |||
| Total Revenue Growth (Q YOY) | 6.55% | |||
| Earnings Growth (Q YOY) | -50.30% | |||
| EPS Diluted (TTM) | 25.61 | |||
| EPS Diluted Growth (Q YOY) | -50.17% | |||
| Balance Sheet | ELV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 34.68B | |||
| Cash Per Share (Q) | $150.07 | |||
| Total Current Assets (Q) | 58.94B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 41.43B | |||
| Current Ratio (Q) | 1.452 | |||
| Book Value Per Share (Q) | $181.62 | |||
| Total Assets (Q) | 116.89B | |||
| Total Current Liabilities (Q) | 40.58B | |||
| Total Debt (Q) | 34.35B | |||
| Total Liabilities (Q) | 75.46B | |||
| Total Common Equity (Q) | 41.32B | |||
| Cash Flow | ELV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -5.17B | |||
| Cash from Financing (TTM) | 1.19B | |||
| Net Change in Cash (TTM) | 1.76B | |||
| Levered Free Cash Flow (TTM) | 4.38B | |||
| Cash from Operations (TTM) | 5.81B | |||
